Skip to content

Evaluation of gene expression in circulating leukocytes in type 2 diabetes mellitus in western Uttar Pradesh

Evaluation of sirt1 and sirt4 gene expression in circulating leukocytes in type 2 diabetes mellitus in western Uttar Pradesh - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/10/096395
Enrollment
52
Registered
2025-10-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications

Interventions

Intervention1: Nil: Nil Control Intervention1: Nil: Nil

Sponsors

Government Institute of Medical Sciences (GIMS)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults aged between 35 to 60 years. 1.Diagnosed cases of uncontrolled Type 2 Diabetes Mellitus as per ADA criteria and with HbA1c levels greater than or equal 7 percent will be collected from dept of Medicine. 2.Willing to provide written informed consent. 3.For control group: age- and sex-matched apparently healthy individuals without a history of diabetes.

Exclusion criteria

Exclusion criteria: 1.Patients with Type 1 Diabetes Mellitus or other forms of secondary diabetes. 2.Individuals with acute or chronic infections, inflammatory diseases, hypertension or malignancies. 3.Patients with renal disease, liver disease, or recent cardiovascular disease, smocker. 4.Pregnant or lactating women. 5.Individuals on immunosuppressive therapy or antioxidant supplements, lipid lowering drugs. 6.Participants unwilling to give informed consent or adhere to study procedur

Design outcomes

Primary

MeasureTime frame
To compare the gene expression levels of SIRT1 and SIRT4 between T2DM patients and apparently healthy controlsTimepoint: At the time of Enrollment only

Secondary

MeasureTime frame
1. To assess biochemical parameters including insulin,Superoxide dismutase 2,Interleukin 4 ,HOMA-IR in T2DM patient & apparently healthy controls. 2.To correlate the insulin,Superoxide dismutase 2,interleukin 4 & HOMA-IR with SIRT1 ,SIRT4 expression in T2DM patient & apparently healthy controls.Timepoint: At the time of Enrollment only

Countries

India

Contacts

Public ContactDr Fatima Iram

Government Institute of Medical Sciences (GIMS)

iramfatima2@gmail.com9971528771

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026